Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia

Peptides. 2002 Dec;23(12):2227-34. doi: 10.1016/s0196-9781(02)00262-0.

Abstract

PACAP exerts neuroprotective effects under various neurotoxic conditions in vitro. In vivo, it reduces brain damage after global and transient focal ischemia. The present study investigated whether PACAP has neuroprotective effects when applied before the onset of permanent ischemia. Rats were given bolus injections of PACAP38 intracerebroventricularly, and then underwent permanent middle cerebral artery occlusion. The results show that 2 microg of PACAP significantly reduced the infarct size measured 12 and 24h after the onset of ischemia. No further reduction was obtained by a 7-day pretreatment. PACAP also ameliorated certain sensorimotor deficits. Our present study provides further evidence for the neuroprotective effects of PACAP, and implies that it might be a promising preventive therapeutic agent in ameliorating ischemic brain damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Pressure / physiology
  • Body Temperature / physiology
  • Brain Infarction / prevention & control*
  • Brain Ischemia / physiopathology*
  • Dose-Response Relationship, Drug
  • Injections, Intraventricular
  • Male
  • Neuropeptides / administration & dosage
  • Neuropeptides / pharmacology*
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacology*
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Rats
  • Rats, Wistar

Substances

  • Adcyap1 protein, rat
  • Neuropeptides
  • Neuroprotective Agents
  • Pituitary Adenylate Cyclase-Activating Polypeptide